36results about How to "Reduce vitality" patented technology

The invention provides a polypeptide and application thereof in preparation of a medicine for preventing and / or treating alcoholic liver injury. The polypeptide is safe and free of side effects, can remarkably reduce the content of malondialdehyde (MDA), improve the activity of superoxide dismutase (SOD), improve the content of glutathione (GSH), reduce the activity of glutamic-pyruvic transaminase (ALT), reduce the activity of aspartate transaminase (AST) and reduce the activity of lactic dehydrogenase (LDH), and is very suitable for preparing the medicine for preventing and / or treating the alcoholic liver injury.

The invention relates to the field of biological medicine, and discloses application of a biphenyl cyclooctene lignan compound and a chemotherapy sensitizing drug. The biphenyl cyclooctene lignan compound can be used for preparing a chemotherapy sensitizing drug, and the chemotherapy sensitizing drug is an ovarian cancer chemotherapy sensitizing drug, and can improve the sensitivity of cells to paclitaxel and inhibit the activity, proliferation and migration of the cells. The biphenyl cyclooctene lignan compound is combined with paclitaxel, so that the cell activity of the ovarian cancer paclitaxel drug-resistant cell A2780 / Taxol can be remarkably reduced, and the cell survival rate is only 31.13%. The combination of the biphenyl cyclooctene lignan compound and paclitaxel can also be used for preparing chemotherapy sensitizing drugs.

The invention discloses application of a gene MtPrx38 in regulation and control of growth, development and quality of forage grass. The method comprises the following steps: carrying out genome PCR (Polymerase Chain Reaction) identification to obtain homozygotes MtPrx38-1 and MtPrx38-2 of the medicago truncatula MtPrx38 gene mutant; the expression quantity of the MtPrx38 gene detected by RT-PCR (Reverse Transcription-Polymerase Chain Reaction) is obviously reduced, and compared with wild medicago truncatula, the peroxidase activity of the mutant homozygotes MtPrx38-1 and MtPrx38-2 is obviously reduced. Compared with wild medicago truncatula, the MtPrx38 gene mutant has the advantages that the root length, the lateral root number, the plant height, the branch number, the leaf area and the secondary branch number are obviously increased; the flowering time is advanced; the lignin content and the cellulose content are obviously reduced, which indicates that the gene MtPrx38 has the functions of regulating and controlling the growth, development and quality of forage grass. The method has application prospects in the aspects of promoting growth and development of forage grass, improving forage grass quality and the like.

The invention relates to the technical field of ovarian granule cell apoptosis, and discloses a method for regulating oxidative stress induced sheep ovarian granule cell apoptosis by using allicin, and the method comprises the following steps: firstly preparing a culture solution, then preparing an allicin stock solution, and identifying sheep ovarian granule cells; the method comprises the following steps: firstly, measuring the activity of ovarian granular cells after independent treatment of H2O2 and allicin, determining the optimal treatment time and concentration of H2O2 and allicin, then carrying out co-treatment of H2O2 and allicin, detecting the apoptosis of the granular cells by using flow cytometry, detecting the expression of apoptosis-related genes by using real-time fluorescent quantitative PCR, detecting the secretion of steroid hormones by using ELISA, and carrying out data analysis. The invention solves the problems that in the prior art, an effective regulation and control method for ovarian granular cell apoptosis induced by oxidative stress is lacked, and traditional medicines possibly have large side effects, unobvious effects and the like.

The invention relates to the technical field of medicines, in particular to a traditional Chinese medicine composition for relieving gout and application thereof. The invention provides a traditional Chinese medicine composition for relieving gout. The traditional Chinese medicine composition comprises the following components in parts by mass: 8-12 parts of an American ginseng extract, 3-6 parts of a poria cocos extract, 6-9 parts of a turmeric extract, 0.8-1.2 parts of a dried ginger extract, 7-13 parts of a cyclocarya paliurus extract, 6-10 parts of a salted cortex phellodendri extract, 4-8 parts of a gynura procumbens extract, 8-12 parts of a nine-processed rhizoma polygonati extract, 8-12 parts of a coix seed extract and 2-6 parts of a corn stigma extract. The traditional Chinese medicine composition can effectively reduce the activity of xanthine oxidase and the content of uric acid in blood, so that gout is relieved, and the effect of the traditional Chinese medicine composition is superior to that of conventionally used western medicine allopurinol.

The invention belongs to the technical field of anti-tumor drugs, and particularly relates to application of allicin in preparation of an anti-tumor drug sensitizer and a tumor chemotherapy pharmaceutical composition, an A549 cell strain, a paclitaxel drug-resistant cell model A549 / Taxol and a tumor-bearing mouse model are established, and in-vivo and in-vitro pharmacodynamic research finds that the allicin can effectively inhibit cell proliferation and has a good anti-tumor effect. The apoptosis is induced, and the drug resistance of paclitaxel is reversed. The compound inhibits P-gp expression, reduces drug efflux and destroys cell autophagy. Particularly, allicin inhibits cathepsin B (CTSB), destroys lysosome functions, blocks autophagy flux, reduces mitochondrial membrane potential and enhances sensitivity to paclitaxel. The combination of allicin and paclitaxel can significantly inhibit the growth of tumor nodules and reduce the number of tumor nodules, shows the potential of reversing the drug resistance of paclitaxel in vivo, can significantly improve the chemotherapy effect of NSCLC, and has potential clinical application value.

The invention relates to an extraction method of Cinnamomum camphora polysaccharide, which comprises the following steps: crushing Cinnamomum camphora fruits, heating and extracting with water at 65-90 DEG C, concentrating a water extracting solution under reduced pressure, carrying out alcohol precipitation on a concentrated solution, deproteinizing, carrying out alcohol precipitation again, and freeze-drying to obtain the Cinnamomum camphora polysaccharide A; or crushing Cinnamomum camphora fruits, respectively extracting the crushed Cinnamomum camphora fruits with petroleum ether and ethyl acetate at room temperature, carrying out solid-liquid separation, carrying out heating extraction on residues with water at 65-90 DEG C, carrying out vacuum concentration on a water extract, carrying out alcohol precipitation on a concentrated solution, deproteinizing, carrying out alcohol precipitation again, and freeze-drying to obtain Cinnamomum camphora polysaccharide B; the Cinnamomum camphora polysaccharide A and / or the Cinnamomum camphora polysaccharide B are / is the Cinnamomum camphora polysaccharide. The invention also discovers a new application of the camellia oleifera tree polysaccharide, and the extracted camellia oleifera tree polysaccharide has a remarkable treatment effect and no toxic or side effect, and can be used for development and utilization of anti-oxidative stress drugs, especially liver protection drugs.

The invention belongs to the technical field of microorganisms, and particularly relates to a high-yield high-temperature-resistant pectinase strain and application thereof. The invention provides an aspergillus niger mutant strain AR-11 for producing high-yield and high-temperature-resistant alkaline pectinase, the enzyme activity level of pectinase produced by utilizing the strain for industrial fermentation can reach 8000-8200U / mL or more, the production cost is greatly reduced, and large-scale application, energy conservation and emission reduction of the alkaline pectinase are facilitated. The produced pectinase has high enzyme activity under a high temperature condition, keeps the stability of the enzyme activity in a wide pH value range, can meet the requirements of a pectinase preparation in the aspects of ramie degumming and textile refining, and can be widely applied to the ramie degumming industry.

The invention discloses an m6A demethylase ALKBH1 small-molecule inhibitor as well as a synthesis method and application thereof, and relates to the technical field of pharmacy, and the m6A demethylase ALKBH1 small-molecule inhibitor has a chemical structural formula as shown in a formula (I). The m6A demethylase ALKBH1 small-molecule inhibitor has biological activity, can be combined with ALKBH1 protein in vitro in a dose-dependent manner, reduces ALKBH1 enzyme activity and has nano-friction-level inhibition activity, and meanwhile, the effect of the small-molecule inhibitor on lung cancer cells A549 is verified, so that the m6A demethylase ALKBH1 small-molecule inhibitor has a good application prospect. A wide application prospect is provided for subsequent computer simulation screening, accurate synthesis of the m6A demethylase ALKBH1 small-molecule inhibitor and application of the m6A demethylase ALKBH1 small-molecule inhibitor in resisting diseases caused by ALKBH1 overexpression. # imgabs0 #

The invention discloses a method for separating fibroblasts from human heart tissue, and belongs to the technical field of cell culture. The method comprises the following steps: standing and digesting heart tissues by using digestive juice containing 0.25 mg / mL collagenase II and collagenase IV; and splitting by using a red blood cell lysis solution, resuspending, centrifuging, and discarding the supernatant to obtain the human heart fibroblasts. According to the invention, heart tissues can be fully dissociated, fibroblasts in the heart tissues can be released, and damage to the heart fibroblasts in the digestion process can be reduced to the greatest extent. According to the method, the problems of low cell activity, low cell yield and the like are solved, and the human heart fibroblasts with full cytoplasm and complete cell nucleuses can be obtained 2-4 days after separation. The method is convenient to operate, short in separation time, high in practicability and high in cell quality, and the human heart fibroblasts obtained through separation have wide application prospects in the aspects of cell culture, screening and testing of new drugs, providing of high-quality cell sources and the like.

The invention discloses an NPFR gene-based pomacea canaliculata antifeedant and application thereof, and belongs to the field of prevention and control of agricultural pests. The dsNPFR based on the NPFR gene is designed and synthesized on the basis of an RNAi-mediated NPFR gene silencing technology, by injecting the dsNPFR into the ampullaria gigas, the lethal effect is obvious, the NPFR gene expression quantity, the body weight growth rate, the leaf feeding area, the digestive enzyme activity and the like are remarkably reduced, feeding and growth of the ampullaria gigas are effectively inhibited, a new strategy and a molecular target are provided for research and development of RNAi biopesticides, and the application has a wide application prospect. And a new technical approach is provided for prevention and control of ampullaria gigas invasion hazards.

The invention discloses application of a rice pollen fertility related gene OsMS3 in male sterile line plant breeding. The invention provides a gene OsMS3 related to rice pollen fertility, the nucleotide sequence of the gene is as shown in SEQ ID NO.1, and the coded amino acid sequence is as shown in SEQ ID NO.2. Researches show that the OsMS3 gene can influence rice fertility and has the effect of regulating and controlling rice pollen fertility. After the OsMS3 gene is knocked out from a rice plant, the activity of rice pollen can be remarkably reduced, so that the rice fertility is remarkably reduced, and the gene can be used for creating a rice sterile line and preparing hybrid seeds. The invention provides more gene resources for constructing a novel cross breeding system, and has important significance on breeding of a rice male sterile line.

The invention discloses application of fumaric acid for inhibiting formation of a vibrio parahaemolyticus biological membrane and an inhibition method, and belongs to the field of biological membranes. The invention provides an application of fumaric acid in inhibition of formation of a vibrio parahaemolyticus biological membrane, and proves that the fumaric acid can significantly reduce the ability of vibrio parahaemolyticus to adhere to different foods and the ability of vibrio parahaemolyticus to form a biological membrane on food contact surfaces, weaken the biological membrane quantity of vibrio parahaemolyticus in food nutrition gravy, interfere the activity of bacteria in the biological membrane and inhibit the formation of the vibrio parahaemolyticus biological membrane. The transcription level of related genes of the vibrio parahaemolyticus biological membrane is reduced.

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The invention discloses a wine-making waste heat recovery system in the technical field of wine-making heat energy recovery, which comprises a wine retort, a cooler, a heat storage water tank, a first pipeline and a second pipeline, the wine retort is communicated with the cooler through the first pipeline, and heated water subjected to heat exchange in the cooler is communicated with the heat storage water tank through the second pipeline; the system further comprises a cold storage water tank, a third pipeline and a fermented grain spreading bed, the first end and the second end of the third pipeline are both communicated with the cold storage water tank, part of the pipeline between the first end and the second end of the third pipeline is located in the fermented grain spreading bed, and the system further comprises a heat exchange unit which comprises a first evaporator, a first condenser, a first refrigerant pipe, a first compressor and a first throttling valve. Heat in the cold storage water tank is transmitted to the heat storage water tank through the heat exchange unit. The technical problems of incomplete energy recovery, low recovery rate and production halt caused by high-temperature environment in the prior art are solved, the energy recovery comprehensiveness and recovery rate are improved, and continuous production of Luzhou-flavor liquor in high-temperature seasons is ensured.

The invention provides application of TMEM65 in construction of a myocardial injury animal model and preparation of a medicine for treating myocardial injury. A TMEM65 myocardial cell specific knockout mouse is constructed through a CRISPR / Cas9 technology, and the physiological action of the TMEM65 gene in myocardial cells can be more accurately researched. By observing the phenotypic change of the TMEM65 myocardial cell specific knockout mouse, the effect and mechanism of TMEM65 in the generation and development of sepsis can be explored. Furthermore, experiments show that TMEM65 overexpression significantly improves the decrease of LPS-induced myocardial cell viability, reduces LDH release, and reduces the apoptosis rate, thereby proving the hypothesis that TMEM65 plays a protective role in sepsis myocardial injury.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of Epitulipinolide dipoxide in preparation of a medicine for preventing and treating bladder cancer. The Epitulipinolide dipoxide disclosed by the invention can cause death of bladder cancer cells, reduce the activity of the bladder cancer cells, inhibit cloning and clustering of the bladder cancer cells, inhibit migration of the bladder cancer cells, inhibit invasion of the bladder cancer cells, promote apoptosis of the bladder cancer cells and promote autophagy of the bladder cancer cells; meanwhile, the Epitulipinolide dipolide and the bladder cancer cells have 140 identical targets, so that the Epitulipinolide dipolide and the bladder cancer cell targets have high target binding potential, and particularly, the Epitulipinolide dipolide can inhibit the ERK / MAPK signal channel of the bladder cancer cells so as to achieve the effect of preventing and treating the bladder cancer.

The invention relates to the technical field of animal model construction, in particular to a construction method and application of a gene editing mouse model for studying calcium library function and low fertility in mature sperms.The model is characterized in that tamoxifen is used for inducing, a Ddx4ERT2 promoter is used for driving Cre recombinase expression, three subtypes of IP3R are specifically knocked out in sperms at the same time, and the mouse model is obtained. The method is used for researching the action and mechanism of the subtype in male fertility. After the model mouse is subjected to two rounds of induced knockout, the fertility is severely damaged, the sperm quantity and movement level are reduced, and the acrosome reaction is abnormal, so that the model is a good model for evaluating the sperm dysfunction, and is expected to be used for screening treatment drugs for improving the sperm dysfunction, especially male sterility diseases caused by advanced acrosome reaction in the future. In addition, through screening optimization of an IP3R agonist and a calcium signal detection platform, it is further confirmed that the mouse model is a good model for studying sperm calcium library mediated calcium signals.

The invention discloses application of gardenia-derived extracellular vesicles in preparation of drugs for preventing and treating neurodegenerative diseases, and relates to the field of biological medicines. According to the invention, the gardenia-derived extracellular vesicles are applied to oxidation resistance and neuroprotection, and after being taken, the gardenia-derived extracellular vesicles can significantly improve the activity reduction of rotenone-induced PC12 cells, and effectively reduce the generation of reactive oxygen species (ROS) and superoxide anions (O2 <->) in the rotenone-induced PC12 cells, thereby relieving oxidative stress; in addition, the treatment of the extracellular vesicles derived from gardenia fruits can also significantly reduce DNA breakage and cell membrane damage in nerve cells caused by rotenone treatment, and has an obvious protection effect on nuclei and cell membranes of the nerve cells. Therefore, the extracellular vesicles derived from the gardenia fruits have remarkable oxidation resistance and nerve cell protection potential.

The invention provides an RNA interference fragment of a donkey Eif2s3y gene, an expression vector and application thereof, and relates to the technical field of molecular genetics, the nucleotide sequence of the RNA interference fragment of the donkey Eif2s3y gene is shown as SEQ ID NO: 1 or SEQ ID NO: 2; the RNA interference fragment of the donkey Eif2s3y gene can artificially interfere expression of the donkey Eif2s3y gene, so that generation and development of Y sperms are blocked, and more fertilization opportunities are created for X sperms, so that the proportion of female foals of a first filial generation is increased, the purpose of controlling the gender of offspring foals is achieved, and X sperm cells are not damaged and the activity of the X sperm cells is not reduced. According to the invention, the gender of the offspring is effectively controlled before fertilization, the purpose of controlling the gender of the offspring donkey foals is achieved, the cost is low, and the RNA interference fragment provided by the invention has a relatively good silencing effect on the donkey Eif2s3y gene.

This invention belongs to the field of plant genetic engineering, specifically relating to an isolated nucleic acid molecule encoding the Sapindus mukorossi SmHD-ZIP34 protein and its application. The isolated nucleic acid molecule has a nucleotide sequence as shown in SEQ ID NO.1, or encodes an amino acid sequence as shown in SEQ ID NO.2. This invention reveals for the first time the dual function of this isolated nucleic acid molecule in simultaneously regulating flowering time and sex differentiation in plants. Experiments have shown that overexpression of this nucleic acid molecule in Arabidopsis thaliana significantly promotes flowering and pistil elongation, and inhibits stamen development by downregulating the core pathway of stamen development, leading to a reduction in the number of stamens and pollen abortion. The nucleic acid molecule resource provided by this invention offers an effective solution to the problems of long breeding cycles and low fruit set rates due to male flower dominance in economic forest trees such as Sapindus mukorossi, and can be used to cultivate high-yielding new germplasm with early flowering, fewer males, and more females.

The present invention belongs to the field of biomedicine technology, and discloses a monoclonal antibody and a cytokine composition and its application. The light chain variable region sequence of the ZSCAN4 protein monoclonal antibody provided by the present invention is shown in SEQ ID NO.4, and the heavy chain variable region sequence is shown in SEQ ID NO.5. The cytokine is a cytokine secreted by bone marrow mesenchymal stem cells. In the monoclonal antibody and cytokine composition provided by the present invention, the ZSCAN4 protein monoclonal antibody can specifically bind to the human ZSCAN4 protein, and has the effect of reducing the vitality of colon cancer cells. After using it together with the cytokine, it can effectively reduce the number of colon cancer cell clones in a short time to treat colon cancer. The monoclonal antibody and cytokine composition provided by the present invention has a better inhibitory effect on colon cancer cells than cetuximab, and has a good prospect for medical application.

The invention discloses a traditional Chinese medicine preparation as well as a preparation method and application thereof in reducing blood sugar and blood fat. The traditional Chinese medicine preparation disclosed by the invention not only has relatively good inhibition capability on glycometabolism related enzymes including alpha-amylase and alpha-glucosidase, but also has relatively high inhibition capability on pancreatic lipase and cholesterol esterase for digesting fat, and the inhibition capability is superior to that of various reported single medicinal and edible substance extracts; the inhibition capability of the Erchen decoction is superior to that of a classic prescription Erchen decoction and an Erchen decoction food-grade basic prescription (except the traditional Chinese medicine rhizoma pinellinae The capacity of inhibiting sugar and lipid-related digestive enzymes and the capacity of regulating blood sugar and lipid disorder of the traditional Chinese medicine preparation are superior to the regulating effect of first-line Chinese patent medicine lipid-lowering granules, and the regulating effect of the traditional Chinese medicine preparation has no significant difference (p is less than 0.05) with the regulating effect of a classic prescription Erchen decoction.

The present invention discloses a method for enhancing the ability of α-synuclein (α-Syn) aggregates to destroy cell membranes. 140 μL 0.01M PBS is used to dissolve 1 mg of recombinant human α-Syn, and then 70 μL PBS, healthy personnel, and PD patient plasma are added respectively and incubated at 37 ° C for 4 days under constant temperature oscillation. Acidic phospholipids 1-palmitoyl-2-oleoyl-sn-glycerol-3-phospho-L-serine (POPS) are used as raw materials. Small unilamellar liposomes (SUVs) are prepared by thin film dispersion-ultrasound method, and different concentrations of proteins are incubated with SUVs and SH-SY5Y cells respectively. The ability of α-Syn aggregates formed under different conditions to destroy cell membranes is observed by calcein leakage experiments. The results show that the α-Syn aggregates formed by incubation of PD patient plasma have stronger ability to destroy cell membranes.

The invention provides application of K568 site mutation of Ku80 protein in regulation and control of tumor cell proliferation and radiotherapy sensitivity, and belongs to the technical field of biology. The invention provides any one of the following applications of a substance capable of causing site-directed mutagenesis of a K568 site of Ku80 protein in a body or a cell: inhibiting tumor cell proliferation; dNA damage repair in tumor cells is inhibited; treating tumors; the tumor radiotherapy sensitivity is improved; and preparing tumor chemotherapy drugs. Tests prove that the K568 site mutation of the Ku80 protein can reduce tumor cell activity, inhibit tumor cell proliferation, promote tumor cell apoptosis, inhibit DNA damage repair after tumor cell radiotherapy and improve radiotherapy sensitivity, can be used as a target spot for researching related drugs for treating tumors, and has potential clinical application value.

The invention discloses a petunia anther dominant expression gene PhERF48 and its expression protein and application, and relates to the technical field of plant genetic engineering. The petunia PhERF48 gene disclosed by the invention has a nucleotide sequence as shown in SEQ ID NO.1, and an amino acid sequence of its encoded protein as shown in SEQ ID NO.2. The invention constructs a silencing expression vector of the petunia PhERF48 gene; transforms the constructed silencing expression vector of the petunia anther dominant expression gene PhERF48 into petunia leaves; cultivates, screens and obtains transgenic petunia plants with poor anther development, blocked pollen formation, and a sharp reduction in pollen amount, resulting in male sterility. The results show that the absence of the petunia anther dominant expression gene PhERF48 leads to poor anther development, blocked pollen formation, a sharp reduction in pollen amount, and pollen deformity in petunia flowers, thereby leading to male sterility in petunia.

The present disclosure relates to compositions and related methods for treating CD96 mediated diseases. The present disclosure relates to CD96 binding proteins comprising a heavy chain variable region at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to SEQ ID NO: 86 and a light chain variable region at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to SEQ ID NO: 85.

The invention belongs to the technical field of biology, and discloses a method for activating an ASXL2-PRC2 axis, which is characterized in that adenovirus is injected into seminiferous tubules of a living body through an outgoing tube, and expression of endogenous EZH2 and spermatogenic cell specificity ASXL2 of the living body is activated. The method disclosed by the invention can be used for alleviating damaged sperm motility, increasing sperm penetration and tubulin polymerization, inhibiting sperm abnormality, down-regulating the transcriptional level of a TZ marker, increasing the enrichment of SUZ12, EED and H3K27me3 in CEP162 and CEP290 promoters under an anoxic condition, and retarding hypoxia-induced abnormal spermatogenesis in a germ cell line of an organism and spermatogenic cell activation of an ASXL2-PRC2 axis.

The application provides an application of a CNOT9 expression inhibitor in preparation of a medicine for preventing, alleviating and / or treating liver cancer. It is found for the first time that the mRNA and protein expression levels of CNOT9 in hepatocellular carcinoma (HCC) tissues are significantly higher than those in paracancerous and normal liver tissues, and the high expression is closely related to the prognosis indexes such as the overall survival and progression-free survival of patients, thereby establishing the value of CNOT9 as a liver cancer diagnosis marker and a new treatment target. Based on this, the application provides an application of a CNOT9 inhibitor in preparation of a medicine for preventing, alleviating and / or treating liver cancer. By down-regulating the expression of CNOT9 through siRNA, the proliferation activity, clonogenicity, migration and invasion ability of liver cancer cells HLF can be effectively inhibited. The application further provides a medicine composition comprising the inhibitor, thereby providing a brand-new target and effective intervention strategy for liver cancer treatment, and having a great clinical development prospect and application value.